BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37981695)

  • 1. Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy.
    Li Y; Liu Y; Yang K; Jin L; Yang J; Huang S; Liu Y; Hu B; Liu R; Liu W; Liu A; Zheng Q; Zhang Y
    Cancer Cell Int; 2023 Nov; 23(1):281. PubMed ID: 37981695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
    Gao F; Hu K; Zheng P; Shi H; Ke X
    Cancer Med; 2023 May; 12(9):10267-10279. PubMed ID: 36971051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results.
    Li Z; Yang K; Song Y; Zhao Y; Wu F; Wen X; Li J; Wang X; Xu T; Zheng X; Zheng Q; Wu T
    Front Oncol; 2022; 12():1048296. PubMed ID: 36686744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of
    Porpaczy E; Wohlfarth P; Königsbrügge O; Rabitsch W; Skrabs C; Staber P; Worel N; Müllauer L; Simonitsch-Klupp I; Kornauth C; Rohrbeck J; Jaeger U; Schiefer AI
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
    Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
    Front Oncol; 2021; 11():664421. PubMed ID: 34113569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Yin Z; Zhang Y; Wang X
    Biomark Res; 2021 Jul; 9(1):58. PubMed ID: 34256851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
    Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
    Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
    Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
    Front Immunol; 2022; 13():858590. PubMed ID: 35371098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
    Fu S; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.
    Wei J; Xiao M; Mao Z; Wang N; Cao Y; Xiao Y; Meng F; Sun W; Wang Y; Yang X; Chen L; Zhang Y; Zhu H; Zhang S; Zhang T; Zhou J; Huang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):101. PubMed ID: 35399106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
    Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
    J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
    Harker-Murray PD; Pommert L; Barth MJ
    J Natl Compr Canc Netw; 2020 Aug; 18(8):1125-1134. PubMed ID: 32755987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.